Table 1.
Cohort characteristics
| White | Black | Other | p-value | |
| Total participants | 853 (83.0%) | 165 (16.0%) | 10 (1.0%) | 0.997 |
| Mean age at diagnosis (± SD) | 38.6 ± 12.1 | 41.0 ± 13.2 | 41.3 ± 9.9 | 0.065 |
| Stage | ||||
| 0 | 250 (29.3%) | 48 (29.1%) | 3 (30.0%) | 0.042 |
| I–II | 544 (63.8%) | 91 (55.2%) | 7 (70.0%) | |
| III–IV | 53 (6.2%) | 25 (15.2%) | 0 (0.0%) | |
| Unstaged | 6 (0.7%) | 1 (0.6%) | 0 (0.0%) | |
| Histology - ICC | <0.001 | |||
| Squamous cell carcinoma | 412 (68.3%) | 102 (87.2%) | 2 (28.6%) | |
| Adenocarcinoma | 139 (23.1%) | 6 (5.1%) | 3 (42.9%) | |
| Adenosquamous | 31 (5.1%) | 5 (4.3%) | 2 (28.6%) | |
| Other | 21 (3.5%) | 4 (3.4%) | 0 (0.0%) | |
| Genotypes and lineages of HPVs compared to cervical cancer stage | ||||
| Stage 0 | Stage I-II | Stage III-IV | p-value | |
| HPV type(s)1 | ||||
| HPV16-related | 199 (85.8%) | 377 (72.2%) | 43 (82.7%) | <0.001 |
| HPV18-related | 33 (14.2%) | 145 (27.8%) | 9 (17.3%) | |
| A7 clade1 | 34 (13.6%) | 142 (28.0%) | 13 (20.6%) | <0.001 |
| A9 clade | 216 (86.4%) | 365 (72.0%) | 50 (79.4%) | |
| HPV 16 lineages1 | ||||
| A1–A3; European | 140 (84.8%) | 217 (73.6%) | 26 (76.5%) | 0.037 |
| A4; Asian | 2 (1.2%) | 16 (5.4%) | 1 (2.9%) | |
| B; African (Af1) | 5 (3.0%) | 11 (3.7%) | 2 (5.9%) | |
| C; African (Af2) | 2 (1.2%) | 4 (1.4%) | 1 (2.9%) | |
| D1; North American | 7 (4.2%) | 5 (1.7%) | 2 (5.9%) | |
| D3; Asian American | 9 (5.5%) | 42 (14.2%) | 2 (5.9%) | |
| HPV 16 E6 variants | ||||
| Destabilize protein structure | 10 (6.2%) | 29 (9.4%) | 4 (10.8%) | 0.472 |
| Destabilize E6–E6AP–p53 complex | 27 (16.7%) | 72 (23.3%) | 7 (18.9%) | 0.436 |
| Stabilize E6–E6AP–p53 complex | 4 (2.5%) | 12 (3.9%) | 3 (8.1%) | 0.344 |
| Immunogenic region 1 (E14–I34) | 22 (13.6%) | 81 (26.2%) | 8 (21.6%) | 0.030 |
| Immunogenic region 1 (L45–A68) | 22 (13.6%) | 51 (16.5%) | 5 (13.5%) | 0.649 |
1
Some tumors had more than one HPV type, HPV Clade, and HPV 16 lineage and were excluded from the analysis. Stage 0 samples were not used in survival analyses.